21 Invest is pleased to announce the first acquisition by the recently launched 21 Invest Healthcare fund of a majority stake in Prosol, an Italian-based, internationally recognized leader in the production of food supplements for animal, human, and infant nutrition.

The company has a strong focus on impact and sustainability, as it is specialized in developing and producing food supplements which promote animal and human health by strengthening their immune systems and thereby reducing the use of antibiotics in animals and CO₂ emissions from animal sources, whilst also contributing to the preservation of marine ecosystems.

Thanks to their positive effects on immune systems and cellular health, these products are also used for human consumption.

The company’s production facility, employing around 40 people, is managed according to strict environmental sustainability criteria, with a particular focus on energy efficiency and water impact reduction.

In 2024 the company exceeded € 28 million in turnover, 80% of which was generated internationally, with Germany and Switzerland as main markets outside Italy.

21 Invest will support the current management led by its CEO and minority shareholder Mr. Daniele Bonvicini, who has worked for the company for over 30 years.

Under the stewardship of 21 Invest, Prosol will continue its growth strategy and consolidate its leadership in the yeast-based ingredient segment for animal nutrition, strength production capacity, develop innovative probiotic solutions for aquaculture, and expand internationally into additional high-potential markets.

This investment is fully aligned with the impact investing strategy of the 21 Invest Healthcare fund, which pursues both sustainable investment goals and tailored impact objectives for the companies it invests in.

Alessandro Benetton, Founding Managing Partner of 21 Invest, comments: "Over the years, by supporting the growth of ProductLife Group and SIFI, we have seen how investments in health and wellness can generate value and a positive social impact. With Prosol, we strengthen our commitment to sustainable nutrition, continuing to look with increased interest at growing sectors linked to health and wellness.”

Stefania Petruccioli, Partner at 21 Invest Healthcare, comments: "We are thrilled that Prosol is the first investment of our fund dedicated to the healthcare sector. The company perfectly embodies the values we seek: scientific know-how, long-term entrepreneurial vision, and a strong commitment to sustainability. Together with the management team, we aim to accelerate its international growth and promote innovative solutions for a healthier and more responsible food chain, for both animals and humans.”

Daniele Bonvicini, CEO of Prosol, added: “The partnership with 21 Invest marks a crucial step to accelerate the future of Prosol. We share an ambitious strategic plan aimed at creating a European leader in yeast-based nutraceutical solutions for animal and human health. We are fully aligned and ready to seize the opportunities ahead of us, strengthened by the support and experience of 21 Invest."